Observational cohort following people with Parkinson's disease and multiple system atrophy in Shanghai
Follows people with Parkinson's disease and multiple system atrophy over time through tests and samples.
Plain-language title generated from the registry record
Registry title: Shanghai Clinical Cohort - Parkinson's Disease (Reserve)
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT07353463
- Record updated
- 5 March 2026
- Original description
The goal of this observational cohort studyis to establish a high-quality clinical cohort of Parkinson's disease (PD) and multiple system atrophy (MSA) patients in Shanghai, in order to improve early diagnosis, precise subtyping, disease monitoring, and to provide a resource for translational research and novel therapy development.Read full original descriptionShow less
Shanghai Clinical Cohort - Parkinson's Disease (Reserve)
The goal of this observational cohort studyis to establish a high-quality clinical cohort of Parkinson's disease (PD) and multiple system atrophy (MSA) patients in Shanghai, in order to improve early diagnosis, precise subtyping, disease monitoring, and to provide a resource for translational research and novel therapy development.
The main questions it aims to answer are:
* Can multimodal data (clinical, imaging, electrophysiology, biospecimens, and genetics) help identify early biomarkers for PD and MSA? * Can precise subtyping and long-term monitoring predict disease progression and therapeutic response? Researchers will compare 600 PD patients and 100 MSA patients to evaluate differences in clinical features, biomarkers, imaging, and prognosis.
Participants will:
* Provide informed consent and complete baseline demographic and medical history collection. * Undergo standardized clinical evaluations, including motor and non-motor symptom scales, cognitive and quality-of-life assessments. * Provide biological samples (blood, saliva, optional CSF). * Receive brain imaging (MRI, optional PET/SPECT) and electrophysiological recordings (EEG, fNIRS). * Participate in longitudinal follow-up visits every 6 months for repeat assessments.
This study will create a sustainable, multicenter, and sharable cohort platform to support early identification, personalized intervention, and therapeutic development for neurodegenerative diseases
Inclusion Criteria for Clinical PD Group:; Patients with a clinical diagnosis of Parkinson's disease (PD) according to the _Chinese Diagnostic Criteria for Parkinson's Disease (2016 edition)_; Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments; Provision of written informed consent; Inclusion Criteria for Clinical MSA Group:; Patients with a clinical diagnosis or clinically probable multiple system atrophy (MSA) according to the Chinese Expert Consensus on the Diagnostic Criteria for MSA (2022); Willingness to undergo biospecimen collection, including cerebrospinal fluid (optional), blood, and saliva, and to complete neuroimaging examinations (MRI, PET/SPECT) and disease-specific clinical assessments; Provision of written informed consent; Exclusion Criteria for All Participants:; Patients with an unclear or uncertain diagnosis; History of stroke, head trauma, hydrocephalus, brain tumor, intracranial hypertension, or intracranial surgery; Evidence of intracranial organic lesions on CT/MRI; Severe anxiety, depression, or schizophrenia; Severe comorbidities involving the heart, lungs, liver, kidneys, endocrine system, or hematological system; Presence of aphasia, severe dysarthria, or other conditions that significantly impair clinical assessments; Anticipated poor compliance.